Pub Date : 2025-10-30DOI: 10.1016/j.clbc.2025.10.018
Lingling Ye, Yan Dai, Liushan Chen, Yuqi Liang, Jiafa He, Shenying Chen, Xue Song, Rui Xu, Qianjun Chen
CDK4/6 inhibitors combined with endocrine therapy have become the standard first-line and second-line therapy for advanced HR+/HER2- breast cancer. This study aimed to evaluate the impact of HER2 low expression on the efficacy of breast cancer patients treated with CDK4/6 inhibitors. We systematically searched 4 major databases and important conference proceedings up to May 2025, and screened out studies that reported the progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in HR+/HER2-low breast cancer patients and HR+/HER2-zero breast cancer patients treated with CDK4/6 inhibitors. We calculated the pooled hazard ratio (HR) and its 95% confidence interval (CI). A total of 18 studies involving 8461 patients were finally included. Among them, HER2-low breast cancer patients accounted for 41.25% of the sample, and HER2-zero breast cancer patients accounted for 57.98% of the sample. The results showed that the progression-free survival (PFS) of HR+/HER2-low breast cancer patients treated with the combination of CDK4/6 inhibitors and endocrine therapy was significantly lower than that of HR+/HER2-zero breast cancer patients (HR = 1.19, 95% CI, 1.10-1.28, P < .0001). Further subgroup analysis indicated that among HER2-low patients, whether they received first-line treatment, subsequent treatment, or were treated with Ribociclib, their prognosis was worse. Analysis of OS showed no statistically significant difference between groups (HR = 1.00, 95% CI, 0.93-1.07, P = .93). Similarly, no significant differences were observed in ORR. In addition, no significant differences in the PFS were observed in HR+/HER2-low breast cancer patients, regardless of whether the HER2 status changed due to treatment, the presence of visceral metastases. In conclusion, among patients receiving CDK4/6 inhibitor combined with endocrine therapy, HER2-low status was associated with significantly shorter PFS but not with significant differences in OS or ORR. However, it is worth noting that most of these studies are retrospective and real-world studies, with limited adjustments for confounding factors, and the statistical power of testing may be insufficient.
{"title":"Effect of HER2-Low Expression on the Efficacy of CDK4/6 Inhibitors in Breast Cancer: A Meta-Analysis.","authors":"Lingling Ye, Yan Dai, Liushan Chen, Yuqi Liang, Jiafa He, Shenying Chen, Xue Song, Rui Xu, Qianjun Chen","doi":"10.1016/j.clbc.2025.10.018","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.10.018","url":null,"abstract":"<p><p>CDK4/6 inhibitors combined with endocrine therapy have become the standard first-line and second-line therapy for advanced HR+/HER2- breast cancer. This study aimed to evaluate the impact of HER2 low expression on the efficacy of breast cancer patients treated with CDK4/6 inhibitors. We systematically searched 4 major databases and important conference proceedings up to May 2025, and screened out studies that reported the progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in HR+/HER2-low breast cancer patients and HR+/HER2-zero breast cancer patients treated with CDK4/6 inhibitors. We calculated the pooled hazard ratio (HR) and its 95% confidence interval (CI). A total of 18 studies involving 8461 patients were finally included. Among them, HER2-low breast cancer patients accounted for 41.25% of the sample, and HER2-zero breast cancer patients accounted for 57.98% of the sample. The results showed that the progression-free survival (PFS) of HR+/HER2-low breast cancer patients treated with the combination of CDK4/6 inhibitors and endocrine therapy was significantly lower than that of HR+/HER2-zero breast cancer patients (HR = 1.19, 95% CI, 1.10-1.28, P < .0001). Further subgroup analysis indicated that among HER2-low patients, whether they received first-line treatment, subsequent treatment, or were treated with Ribociclib, their prognosis was worse. Analysis of OS showed no statistically significant difference between groups (HR = 1.00, 95% CI, 0.93-1.07, P = .93). Similarly, no significant differences were observed in ORR. In addition, no significant differences in the PFS were observed in HR+/HER2-low breast cancer patients, regardless of whether the HER2 status changed due to treatment, the presence of visceral metastases. In conclusion, among patients receiving CDK4/6 inhibitor combined with endocrine therapy, HER2-low status was associated with significantly shorter PFS but not with significant differences in OS or ORR. However, it is worth noting that most of these studies are retrospective and real-world studies, with limited adjustments for confounding factors, and the statistical power of testing may be insufficient.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145582023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-28DOI: 10.1016/j.clbc.2025.10.015
Wenyan Zhang, Zhongzhu Tang
{"title":"Comment on “The USP8/CEP55/CHMP6 Axis Orchestrates Triple-Negative Breast Cancer Progression by Regulating Ferroptosis and Macrophage M2 Polarization”","authors":"Wenyan Zhang, Zhongzhu Tang","doi":"10.1016/j.clbc.2025.10.015","DOIUrl":"10.1016/j.clbc.2025.10.015","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 1","pages":"Pages 23-26"},"PeriodicalIF":2.5,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145573167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-28DOI: 10.1016/j.clbc.2025.10.016
Kadri Altundag
{"title":"Cryotherapy in Taxane-Induced Peripheral Neuropathy: The Need for Objective Validation","authors":"Kadri Altundag","doi":"10.1016/j.clbc.2025.10.016","DOIUrl":"10.1016/j.clbc.2025.10.016","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 1","pages":"Page 27"},"PeriodicalIF":2.5,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145573276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-27DOI: 10.1016/j.clbc.2025.10.014
Arin Natania S
{"title":"Letter to the editor regarding the article “Overweight and Risk of Recurrence Following Neoadjuvant Chemotherapy in Breast Cancer”","authors":"Arin Natania S","doi":"10.1016/j.clbc.2025.10.014","DOIUrl":"10.1016/j.clbc.2025.10.014","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 1","pages":"Page 22"},"PeriodicalIF":2.5,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145537039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-24DOI: 10.1016/j.clbc.2025.10.013
Jiongjiong Zhang
{"title":"Diagnostic Heterogeneity and Healthcare Access Disparities: Latent Systemic Bias in Global Estimates of Male Breast Cancer Burden","authors":"Jiongjiong Zhang","doi":"10.1016/j.clbc.2025.10.013","DOIUrl":"10.1016/j.clbc.2025.10.013","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 1","pages":"Pages 1-2"},"PeriodicalIF":2.5,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145537037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-23DOI: 10.1016/j.clbc.2025.10.010
Esin Aysel Kandemir , Rebekka Adam , Julia Roeper , Lena Ansmann , Petra Hülper , Eduard Malik , Claus-Henning Köhne , Frank Griesinger
Background
Multidisciplinary care is essential for the management of breast cancer. Multidisciplinary tumor boards (MTBs) can improve the health outcomes in breast cancer; however, the association of adherence to MTB recommendations with survival time has not been studied.
Methods
This is a retrospective observational study of patients with breast cancer diagnosed between 2014 and 2018 and discussed in the MTB meetings at 2 breast cancer centers certified by the German Cancer Society. Primary endpoints were adherence rate to MTB recommendations and disease-free survival (DFS). The secondary endpoint was overall survival (OS). Kaplan–Meier survival analysis and Cox proportional hazard modelling were used. Ethics approval was obtained from the Ethical Commission of Carl von Ossietzky University of Oldenburg (2018-100).
Results
In total, 1563 patients with breast cancer were included in the study. The adherence rate to MTB recommendations was 89.6%. The most common reason for nonadherence was patient preference (122 out of 162 nonadherent patients, 75.3%). There was a statistically significant difference in DFS and OS between adherent and nonadherent patients (log-rank test, P < .05). In the multivariate analysis, adherence was a significant predictor of DFS but not OS.
Conclusion
Adherence to MTB recommendations demonstrated an improved DFS and OS in patients with breast cancer in the univariate analysis. In the multivariate analysis, adherence was a significant predictor of DFS but not OS. This suggests further research is needed to determine the factors underlying behind the survival time of patients with breast cancer.
{"title":"Adherence to Multidisciplinary Tumor Board (MTB) Recommendations in Patients With Breast Cancer: The Results From Two Cancer Centers in Germany","authors":"Esin Aysel Kandemir , Rebekka Adam , Julia Roeper , Lena Ansmann , Petra Hülper , Eduard Malik , Claus-Henning Köhne , Frank Griesinger","doi":"10.1016/j.clbc.2025.10.010","DOIUrl":"10.1016/j.clbc.2025.10.010","url":null,"abstract":"<div><h3>Background</h3><div>Multidisciplinary care is essential for the management of breast cancer. Multidisciplinary tumor boards (MTBs) can improve the health outcomes in breast cancer; however, the association of adherence to MTB recommendations with survival time has not been studied.</div></div><div><h3>Methods</h3><div>This is a retrospective observational study of patients with breast cancer diagnosed between 2014 and 2018 and discussed in the MTB meetings at 2 breast cancer centers certified by the German Cancer Society. Primary endpoints were adherence rate to MTB recommendations and disease-free survival (DFS). The secondary endpoint was overall survival (OS). Kaplan–Meier survival analysis and Cox proportional hazard modelling were used. Ethics approval was obtained from the Ethical Commission of Carl von Ossietzky University of Oldenburg (2018-100).</div></div><div><h3>Results</h3><div>In total, 1563 patients with breast cancer were included in the study. The adherence rate to MTB recommendations was 89.6%. The most common reason for nonadherence was patient preference (122 out of 162 nonadherent patients, 75.3%). There was a statistically significant difference in DFS and OS between adherent and nonadherent patients (log-rank test, <em>P</em> < .05). In the multivariate analysis, adherence was a significant predictor of DFS but not OS.</div></div><div><h3>Conclusion</h3><div>Adherence to MTB recommendations demonstrated an improved DFS and OS in patients with breast cancer in the univariate analysis. In the multivariate analysis, adherence was a significant predictor of DFS but not OS. This suggests further research is needed to determine the factors underlying behind the survival time of patients with breast cancer.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 1","pages":"Pages 13-21"},"PeriodicalIF":2.5,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145537036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-22DOI: 10.1016/j.clbc.2025.10.012
S. Dhanya Dedeepya , Vaishali Goel , Nivedita Nikhil Desai
{"title":"Comment on “Sequential Therapy With HER2 Tyrosine Kinase Inhibitors in Patients With HER2-Positive Metastatic Breast Cancer”","authors":"S. Dhanya Dedeepya , Vaishali Goel , Nivedita Nikhil Desai","doi":"10.1016/j.clbc.2025.10.012","DOIUrl":"10.1016/j.clbc.2025.10.012","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 1","pages":"Pages 3-4"},"PeriodicalIF":2.5,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145537038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-22DOI: 10.1016/j.clbc.2025.10.009
Noëlle J M C Vrancken Peeters, Marianne J Heins, Gioele Re, Marleen Kok, Iris M C van der Ploeg, Winette T A van der Graaf, Olga Husson
Background: The prognosis for adolescent and young adult (AYA) breast cancer patients has increased significantly. Research concerning long-term health problems is especially relevant given the long life expectancy of these young patients. This study aimed to compare the long-term health issues registered by general practitioners (GPs) of AYA breast cancer survivors to age-matched controls.
Methods: Data of all female AYAs diagnosed with invasive breast cancer between 1999 and 2020 were obtained from the Netherlands Cancer Registry (NCR) and linked with longitudinal data on health problems recorded by GPs organized in the Nivel Primary Care Database (Nivel-PCD). A female normative sample was obtained from the Nivel Primary Care Database (Nivel-PCD). Cox proportional hazard models were used to compare the hazard of a GP consult for a specific health condition after diagnosis between AYA breast cancer survivors and controls.
Results: A total of 793 AYA breast cancer survivors (mean age 35.3 years, mean follow-up 4.7 years) and 2379 controls were included. AYA breast cancer survivors had significantly increased hazards of consulting the GP for eye (HR = 1.25), musculoskeletal (HR = 1.12), psychological/psychiatric (HR = 1.18), skin (HR = 1.26), and urinary tract conditions (HR = 1.20) and decreased hazards for pregnancy-related conditions (HR = 0.47) and conditions of the female genital system (HR = 0.85) compared to controls.
Conclusion: AYA breast cancer survivors face a higher risk of various long-term health challenges compared to age-matched controls, including physical and psychological conditions. This emphasizes the need for the development of multidisciplinary follow-up programs tailored to the specific and ongoing health needs of this young population.
{"title":"Long-Term Health Issues of Adolescent and Young Adult Breast Cancer Survivors.","authors":"Noëlle J M C Vrancken Peeters, Marianne J Heins, Gioele Re, Marleen Kok, Iris M C van der Ploeg, Winette T A van der Graaf, Olga Husson","doi":"10.1016/j.clbc.2025.10.009","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.10.009","url":null,"abstract":"<p><strong>Background: </strong>The prognosis for adolescent and young adult (AYA) breast cancer patients has increased significantly. Research concerning long-term health problems is especially relevant given the long life expectancy of these young patients. This study aimed to compare the long-term health issues registered by general practitioners (GPs) of AYA breast cancer survivors to age-matched controls.</p><p><strong>Methods: </strong>Data of all female AYAs diagnosed with invasive breast cancer between 1999 and 2020 were obtained from the Netherlands Cancer Registry (NCR) and linked with longitudinal data on health problems recorded by GPs organized in the Nivel Primary Care Database (Nivel-PCD). A female normative sample was obtained from the Nivel Primary Care Database (Nivel-PCD). Cox proportional hazard models were used to compare the hazard of a GP consult for a specific health condition after diagnosis between AYA breast cancer survivors and controls.</p><p><strong>Results: </strong>A total of 793 AYA breast cancer survivors (mean age 35.3 years, mean follow-up 4.7 years) and 2379 controls were included. AYA breast cancer survivors had significantly increased hazards of consulting the GP for eye (HR = 1.25), musculoskeletal (HR = 1.12), psychological/psychiatric (HR = 1.18), skin (HR = 1.26), and urinary tract conditions (HR = 1.20) and decreased hazards for pregnancy-related conditions (HR = 0.47) and conditions of the female genital system (HR = 0.85) compared to controls.</p><p><strong>Conclusion: </strong>AYA breast cancer survivors face a higher risk of various long-term health challenges compared to age-matched controls, including physical and psychological conditions. This emphasizes the need for the development of multidisciplinary follow-up programs tailored to the specific and ongoing health needs of this young population.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145502472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comment on: Prognostic Ability of the Indication for Adjuvant Systemic Therapy Based on Preoperative Biopsy and the Surgical Excision Specimen in Cases of Small Breast Tumors (CONSCIENCE): A Retrospective Cohort Study.","authors":"Xuezheng Zhu, Daquan Liao, Shiye Huang, Yubin Feng, Ziye Zhuang","doi":"10.1016/j.clbc.2025.10.007","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.10.007","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145512314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating adverse effect of taxane-based chemotherapy, often persisting long after treatment completion. This study evaluates the efficacy of continuous foot cooling with an adjustable temperature wrap during taxane infusion to prevent CIPN in breast cancer patients.
Methods
In this open-label randomized controlled trial, 120 patients with stage I to III breast cancer undergoing paclitaxel-based chemotherapy were randomly assigned to an intervention group receiving continuous feet cooling (13°C-16°C) initiated 30 minutes before and maintained until 15 minutes after chemotherapy infusion, alongside standard care, or to a control group receiving standard care alone. CIPN was assessed using the modified EORTC QLQ-CIPN20 questionnaire at 6 weeks (t1), 12 weeks (t2), and 3 months post-treatment (t3).
Results
Baseline characteristics were balanced between groups. The intervention group demonstrated significantly lower-limb CIPN scores compared to controls at all time points: week 6 (21.58 ± 5.89 vs. 26.28 ± 7.78; P < .001), week 12 (22.75 ± 7.15 vs. 28.56 ± 6.99; P < .001), and 3 months post-treatment (19.73 ± 5.90 vs. 26.65 ± 19.48; P < .001). The number needed to treat (NNT) was 7, indicating a moderate protective effect. Foot cooling was well tolerated, with no differences in chemotherapy dose modifications.
Conclusion
Continuous foot cooling during chemotherapy significantly reduces the incidence of CIPN and may improve treatment adherence. Larger multicenter trials are needed to validate these findings.
Clinical Trial Registration
Iranian Registry of Clinical Trials (IRCT) number IRCT20231108059991N1.
{"title":"Feet Cooling As a Preventive Strategy against Chemotherapy-Induced Peripheral Neuropathy in Advanced Breast Cancer Patients: A Randomized Clinical Trial","authors":"Fatemeh Asadi , Elaheh Emadi , Reza Chaman , Pejman Porouhan , Mahboobeh Nematshahi , Babak PeyroShabany , Mohammad Salari Zare , Seyed Alireza Javadinia","doi":"10.1016/j.clbc.2025.10.008","DOIUrl":"10.1016/j.clbc.2025.10.008","url":null,"abstract":"<div><h3>Background</h3><div>Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating adverse effect of taxane-based chemotherapy, often persisting long after treatment completion. This study evaluates the efficacy of continuous foot cooling with an adjustable temperature wrap during taxane infusion to prevent CIPN in breast cancer patients.</div></div><div><h3>Methods</h3><div>In this open-label randomized controlled trial, 120 patients with stage I to III breast cancer undergoing paclitaxel-based chemotherapy were randomly assigned to an intervention group receiving continuous feet cooling (13°C-16°C) initiated 30 minutes before and maintained until 15 minutes after chemotherapy infusion, alongside standard care, or to a control group receiving standard care alone. CIPN was assessed using the modified EORTC QLQ-CIPN20 questionnaire at 6 weeks (t<sub>1</sub>), 12 weeks (t<sub>2</sub>), and 3 months post-treatment (t<sub>3</sub>).</div></div><div><h3>Results</h3><div>Baseline characteristics were balanced between groups. The intervention group demonstrated significantly lower-limb CIPN scores compared to controls at all time points: week 6 (21.58 ± 5.89 vs. 26.28 ± 7.78; <em>P</em> < .001), week 12 (22.75 ± 7.15 vs. 28.56 ± 6.99; <em>P</em> < .001), and 3 months post-treatment (19.73 ± 5.90 vs. 26.65 ± 19.48; <em>P</em> < .001). The number needed to treat (NNT) was 7, indicating a moderate protective effect. Foot cooling was well tolerated, with no differences in chemotherapy dose modifications.</div></div><div><h3>Conclusion</h3><div>Continuous foot cooling during chemotherapy significantly reduces the incidence of CIPN and may improve treatment adherence. Larger multicenter trials are needed to validate these findings.</div></div><div><h3>Clinical Trial Registration</h3><div>Iranian Registry of Clinical Trials (IRCT) number IRCT20231108059991N1.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 1","pages":"Pages 5-12"},"PeriodicalIF":2.5,"publicationDate":"2025-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145537035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号